There are like 360 million shares in the float, seems like if current shareholders were rejecting we would be seeing more than average 447K volume. What Armen is stating is that there needs to be more awareness put out to potential investors regarding how RXMD has evolved tremendously this year and laying out the context for our development this year and the plan for future growth. (i.e. goals, accomplishments, strategy, etc.)